ALESSANDRO GOZZETTI^*, MONICA BOCCHIA

Oncology Research, Vol.31, No.3, pp. 271-274, 2023, DOI:10.32604/or.2023.028668

Abstract Novel drug availability has increased the depth of response and revolutionised the outcomes of multiple myeloma patients. Minimal residual disease evaluation is a surrogate for progression-free survival and overall survival and has become widely used not-only in clinical trials but also in daily patient management. Bone marrow aspiration is the gold standard for response evaluation, but due to the patchy nature of myeloma, false negatives are possible. Liquid biopsy and blood-based minimal residual disease evaluation consider circulating plasma cells, mass spectrometry or circulating tumour DNA. This approach is less invasive, can provide a more comprehensive picture of the disease and… More >

Yang Cao^*, Xu Shi^†, Yingmin Liu^‡, Ren Xu^§, Qing Ai^*

Oncology Research, Vol.27, No.1, pp. 117-124, 2019, DOI:10.3727/096504018X15213031799835

Abstract MicroRNA-338-3p (miR-338-3p) has been reported to be a tumor suppressor in multiple cancer types. However, the biological role of miR-338-3p and its underlying mechanism in multiple myeloma (MM) remain unclear. In the present study, we investigated the biological role and potential of miR-338-3p in MM. We found that miR-338-3p was significantly decreased in newly diagnosed and relapsed MM tissues and cell lines. Overexpression of miR-338-3p in MM cells significantly inhibited proliferation and promoted apoptosis, caspase 3, and caspase 8 activity. Bioinformatics algorithm analysis predicted that cyclin-dependent kinase 4 (CDK4) was a direct target of miR-338-3p, and this was experimentally verified… More >

Yulong Jin^*, Li Xu^*, Xiaodong Wu^†, Juan Feng^*, Mimi Shu^*, Hongtao Gu^*, Guangxun Gao^*, Jinyi Zhang^‡, Baoxia Dong^*, Xiequn Chen^*

Oncology Research, Vol.27, No.6, pp. 729-737, 2019, DOI:10.3727/096504018X15443011011637

Abstract Multiple myeloma (MM) is a hematopoietic malignancy characterized by the clonal proliferation of antibodysecreting plasma cells. Bortezomib (BZM), the first FDA-approved proteasome inhibitor, has significant antimyeloma activity and prolongs the median survival of MM patients. However, MM remains incurable predominantly due to acquired drug resistance and disease relapse. -Catenin, a key effector protein in the canonical Wnt signaling pathway, has been implicated in regulating myeloma cell sensitivity to BZM. Decitabine (DAC) is an epigenetic modulating agent that induces tumor suppressor gene reexpression based on its gene-specific DNA hypomethylation. DAC has been implicated in modulating Wnt/ -catenin signaling by promoting the… More >

R. Kavitha^1,*, N. Viswanathan²

Intelligent Automation & Soft Computing, Vol.33, No.2, pp. 1305-1320, 2022, DOI:10.32604/iasc.2022.022816

Abstract Bone marrow cancer is considered to be the most complex and dangerous disease which results due to an uncontrolled growth of white blood cells called leukocytes. Acute Lymphoblastic Leukemia (ALL) and Multiple Myeloma (MM) are considered to be important categories of bone cancers, which induces a larger number of cancer cells in the bone marrow, results in preventing the production of healthy blood cells. The advent of Artificial Intelligence, especially machine and deep learning, has expanded humanity’s capacity to analyze and detect these increasingly complex diseases. But, accurate detection of cancer cells and reducing the probability of false alarm rates… More >